Share

EORTC’s presence at ESMO 2023

New findings and upcoming EORTC trials in lung, head and neck, breast and rare cancers will be presented at ESMO 2023 in Madrid, highlighting EORTC’s commitment to innovative non-commercial cancer research. Seven abstracts have been accepted, with one of them being an oral presentation. Additionally, EORTC’s Scientific Director, Jan Bogaerts, will delve into the realm of pragmatic trials during a special session on Sunday, 22 October 2023. For a comprehensive overview of EORTC’s activities at ESMO, please refer to the table below.

EORTC presentations:

Presentation title Presentation details
Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints (SISAQOL-IMI): Two years update
Madeline Pe, Belgium
Friday, 20 October 2023 at 2:00 PM
Room: Ávila Auditorium – NCC
Pragmatic Trials
Jan Bogaerts, Belgium
Sunday, 22 October 2023 at 10:15 AM
Room: León Auditorium – Hall 7

EORTC abstracts accepted at ESMO:

Cancer type Abstract Title Presentation Details & Abstract Number
Breast Cancer EORTC BCG 1984 – NOBLE – Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer.
Emanuel Buhrer, Belgium
Saturday, 21 October 2023
Type: Poster Display
Abstract Number: 351TiP
Breast Cancer Deep Learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study.
Christian Esposito, France
Saturday, 21 October 2023
Type: Poster Display
Abstract Number: 2274P
Lung Cancer IMMUcan consortium: focus on the first non-small cell lung cancer (NSCLC) cohort.
Marie Morfouace, Germany
Saturday, 21 October 2023
Type: Poster Display
Abstract Number: 2266P
Rare Cancers Molecular profiling of 991 prospectively recruited patients with rare cancers in EUROPE: First results of ARCAGEN – a EORTC-SPECTA and EURACAN study.
Marie Morfouace, Germany
Sunday, 22 October 2023 at 08:30 AM
Type: Mini Oral session
Room: Santander Auditorium – Hall 9
Abstract Number: 132MO
Head and Neck Carcinoma A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
Rachel Galot, Belgium
Sunday, 22 October 2023
Type: Poster Display
Abstract Number: 935P
Lung Cancer The 1825-EORTC, ALKALINE: Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor.
Laura Mezquita, Spain
Monday, 23 October 2023
Type: Poster Display
Abstract Number: 1509TiP
Lung Cancer The 1920-EORTC-BIORADON study: Molecular characterization of non-small cell lung cancer (NSCLC) and indoor radon exposure in Europe.
Laura Mezquita, Spain
Monday, 23 October 2023
Type: Poster Display
Abstract Number: 1508TiP
Back to news list

Related News

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma